Professional Documents
Culture Documents
Mohammedali Sajun Sem II
Mohammedali Sajun Sem II
ERYTHROCYT
ES
-Mohammedali
Sajun
Sem II
Contents :
Introduction : Biopharmaceuticals and
Erythrocytes
Resealed Erythrocytes as carrier
Methods of Preparation
Characterization
Application
Stability
Case Study
References
Biopharmaceuticals
What are Biopharmaceuticals..?
– All therapeutic, prophylactic and in-vivo diagnostic agents produced
using living organisms or their functional components.
– Antibodies -- Therapeutics
Biconcave discs,
anucleate.
Filled with hemoglobin
(Hb), a protein that
functions in gas transport
Contain the plasma
membrane protein
spectrin and other
proteins that:
– Give erythrocytes their
flexibility
– Allow them to change
shape as necessary
Erythrocytes
RBC membrane is made up of
phospholipid bilayer with
channels and pores for transfer
of ions and gases respectively.
Healthy adult male= 4.5
millions/µml
Healthy adult female= 4.8
millions/µml
Matured RBCs have no nucleus
Ribosome & Mitochondria .
Therefore all space is available
for drug carrier.
Reticulocytes- immature
erythrocytes
Resealed Erythrocytes
Properties as carrier :-
Appropriate size, shape.
Biocompatible & minimum toxic side effects
Minimum leakage before target site is achieved
Should be able to carry broad spectrum of drugs
Appreciable stability during storage period
Should have sufficient space & should carry adequate
amounts of drugs
What is meant by
Resealed/Loaded Erythrocytes..?
Advantages of R.E. :-
A remarkable degree of biocompatibility, particularly when the autologous cells are used for drug loading.
Complete biodegradability and the lack of toxic product(s) resulting from the carrier biodegradation.
Avoidance of any undesired immune responses against the encapsulated drug.
Considerable protection of the organism against the toxic effects of the encapsulated drug, e.g.,
antineoplasms.
Remarkably longer life-span of the carrier erythrocytes in circulation in comparison to the synthetic
carriers
In the optimum condition of the loading procedure, the life-span of the resulting carrier cells may be
comparable to that of the normal erythrocytes.
An easily controllable life-span within a wide range from minutes to months.
Desirable size range and the considerably uniform size and shape.
Protection of the loaded compound from inactivation by the endogenous factors.
Possibility of targeted drug delivery to the RES organs.
Advantages of R.E. :-
Relatively inert intracellular environment .
Availability of knowledge, techniques, and facilities for handling, transfusion, and working with erythrocytes
Possibility of an ideal zero-order kinetics of drug release.
Wide variety of compounds with the capability of being entrapped within the erythrocytes.
Possibility of loading a relatively high amount of drug in a small volume of erythrocytes, which, in turn,
assures the dose sufficiency in clinical as well as animal studies using a limited volume of erythrocyte
samples.
Modification of the pharmacokinetic and pharmacodynamic parameters of the drug [14,17,20,22];
Remarkable decrease in concentration fluctuations in steady state in comparison to the conventional methods
of drug administration which is a common advantage for most of the novel drug delivery systems.
Considerable increase in drug dosing intervals with drug concentration in the safe and effective level for a
relatively long time.
Possibility of decreasing drug side effects
Limitations of R.E. :-
The major problem encountered in the use of biodegradable materials or natural cells as drug carriers is that
they are removed in vivo by the RES as result of modification that occurred during loading procedure in cells.
This, although expands the capability to drug targeting to RES, seriously limits their life-span as long-
circulating drug carriers in circulation and, in some cases, may pose toxicological problems.
The rapid leakage of certain encapsulated substances from the loaded erythrocytes.
Several molecules may alter the physiology of the erythrocyte.
Given that they are carriers of biological origin, encapsulated erythrocytes may present some inherent
variations in their loading and characteristics compared to other carrier systems.
The storage of the loaded erythrocytes is a further problem provided that there are viable cells and need to
survive in circulation for a long time upon re-entry to the host body. Conditioning carrier cells in isotonic
buffers containing all essential nutrients, as well as in low temperatures, the addition of nucleosides or
chelators, lyophilization with glycerol or gel immobilization have all been exploited to overcome this problem.
Possible contamination due to the origin of the blood, the equipment used and the loading environment.
Rigorous controls are required accordingly for the collection and handling of the erythrocytes.
Intravenous Drug Release Mechanisms :
– Passive diffusion into circulation.
– Specialized membrane associated carriers
– Phagocytosis by RES and release into circulation
– Accumulation of drug in RES and slow release from
this system into circulation
– Haemolysis at injection site(if route is other than I.V.)
Damaged or aged RBCs that lose their
flexibility/integrity are destroyed in the
Co-encapsulation of
RES. paramagnetic particles or
Macrophages of the RES where RBCs
are destroyed include:
photosensitive agentsin
– Peritoneal macrophages erythrocytes along with
– Hepatic kupffer cells drug to be targeted
– Alveolar macrophages of lungs
– Peripheral blood monocytes Application of Ultrasound
– Vascular endothelial cells waves
Eg.: Glutaraldehyde (membrane stabilizing
agent) added to loaded RBCs to reduces Site specific antibody
flexibility of the membrane.
Also coating RBC with antibody makes
attachment to erythrocyte
them more recognizable by RES membrane.
Source, Fractionation & Isolation of
Erythrocytes
Amphotericin B
Drug
Increased permeability
RBC Resealed RBC
e.g. Chemical agents
of RBC
Resealing Buffer
Electro-insertion or Electro-encapsulation
+ + Loaded RBC
At 250 C Loading suspension Isotonic NaCl
Pulsation
medium Resealing Buffer
Resealed RBC
Hypertonic Hypotonic
medium medium
Isotonic
medium
Dilutional Haemolysis
0.4% NaCl Drug
RBC Membrane ruptured RBC Loaded RBC
Hypotonic Loading buffer
Hypotonic med
Isotonic med .
Efficiency 1-8% Enzymes
delivery
Washed
Isotonic Osmotic Lysis
Physical rupturing
Drug Isotonic
Chemical Buffer
rupturing
Loaded RBC
Incubation at
250 C
Resealed RBC
80 %
Haematocrit
value
RBC
Placed in dialysis bag Dialysis bag placed in 200ml of lysis buffer
+ with air bubble with mechanical rotator 2hrs. 4c.
Phosphate
buffer
Loading Drug
buffer
Resealed RBC Dialysis bag placed in Resealing buffer with Loaded RBC
mechanical rotator 30 min 37c.
Efficiency 30-45%
Characterization
Characterization
Applications
R.E. used as carrier for :-
– Drugs
– Enzymes
– Peptides and protiens
Novel systems
Nanoerythrosomes
Erythrosomes
Applications
Applications
Applications
Applications
Stability
Membrane stabilizing agents like dimethyl
sulfoxide may be added during preparation.
However they reduce the circulation time of such
erythrocytes as seen earlier.
Other approaches for increasing stability include :
– encapsulation of prodrug that undergoes conversion
into parent drug only at body temperature,
– high glycerol freezing technique and
– reversible immobilization in alginate or gelatin gels.
Marketed Products
Majority of the R.E. products mentioned in this persentation are in the
clinical stage.
These two drugs are used in mycobacterium avium infection and some
bacterial infections in AIDS patients.
A.V. Gothoskar,
– ‘Resealed Erythrocytes - A Review’,
Pharmaceutical Technology, March 2004.
Indian Journal of Pharmaceutical Education & Research Vol. 43(4), Oct-Dec, 2009 , 375-
386